White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
One Percent Rule Checklist For Safer Forex Trading Risk 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
SYDNEY, Australia, April 12, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”), is pleased to announce that it has received a A$492,144 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2016 fiscal year, mainly related to the Company’s TACTI-mel trial, a Phase I clinical study in melanoma using its lead compound IMP321, conducted in Australia.
This follows approval from AusIndustry of Prima’s application for an Advance/Overseas Finding. Due to the Advance Finding, Prima’s projected research and development activities for TACTI-mel in both Australia and overseas are eligible for the R&D Tax Incentive for a period of three years to 30 June 2018.
Prima BioMed will apply the funding towards furthering its current active clinical trial program for lead product, IMP321.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: Australian Investors/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 (0) 422 534 755; [email protected] U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected]
